(Q38176549)

English

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

scientific article published on 07 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

0 references

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

0 references

10

object named as

Maya H Buch

0 references

Cécile Gaujoux-Viala

3

object named as

Cecile Gaujoux-Viala

0 references

9

object named as

Josef S Smolen

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

7

object named as

Laure Gossec

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Robert Landewé

8

object named as

Robert Landewe

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

2

object named as

Sofia Ramiro

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

author name string

Jackie L Nam

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Cecile Gaujoux-Viala

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Kaoru Takase

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Mario Leon-Garcia

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

0 references

publication date

7 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

516-528

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The role of biosimilars in the treatment of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Fatigue in cancer patients compared with fatigue in the general United States population.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Therapies for active rheumatoid arthritis after methotrexate failure

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The importance of reporting disease activity states in rheumatoid arthritis clinical trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204577

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2013-204577

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38176549&oldid=1745941811"